Topic: personalized medicine
ArcherDX has closed on a $60 million financing round to support its companion diagnostic program spanning solid and blood tumors.
Some microRNAs could serve as prognostic markers of Crohn's and open the possibility of developing personalized therapies.
Cancer blood test company Epic Sciences raised $52 million to move its treatment-guiding liquid biopsies toward regulatory approval.
Researchers at Mount Sinai say they’ve identified two biomarkers that may improve the treatment of an aggressive subtype of bladder cancer.
The fund will invest in companies that tap into AI and the internet of things to deliver devices tailored to the biology and lifestyle of individuals.
Scientists at the University of Cambridge have shown in animal models that reprogramming patients’ own skin cells may be an effective way to treat MS.
Notable Labs picked up $10 million for its service that helps identify combination treatments for blood cancer patients.
Gristone Oncology, a biotech-medtech crossover, is working to apply next-generation sequencing, bioinformatics and algorithms to the creation of new cancer immunotherapies.
Singapore’s state-owned investment firm Temasek and Chinese internet tycoon Jack Ma-backed Yunfeng Capital have led a $75 million Series B into WuXi NextCODE.
Scientists at the University of Maryland have identified thousands of cancer-causing genetic mutations using a method that may lead to new targeted treatments.